Physician profile
James Atem
NPI 1760743066
$1,693.77
in general payments reported to CMS, 2019-2025
21 companies · $242 in 2025
The $242 reported for 2025 was more than what 80% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.56 · 2022: $249 · 2023: $686 · 2024: $426 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $253.54 | 2019-2025 | Airsupra, Lokelma, Breztri |
| Janssen Pharmaceuticals, INC | $233.57 | 2022-2024 | Xarelto |
| Pfizer INC. | $192.94 | 2023-2025 | |
| Inari Medical, INC. | $106.35 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbvie INC. | $100.76 | 2023-2024 | Teflaro, Dalvance |
| Alexion Pharmaceuticals, INC. | $100.54 | 2023 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.06 | 2022-2025 | Jardiance |
| Janssen Scientific Affairs, LLC | $90.17 | 2023 | Xarelto |
| Novo Nordisk INC | $84.44 | 2023-2024 | Ozempic, Rybelsus |
| Neurelis, INC. | $71.51 | 2023-2024 | Valtoco |
| Scpharmaceuticals INC. | $67.65 | 2025 | |
| Novartis Pharmaceuticals Corporation | $46.44 | 2022-2023 | |
| Baxter Healthcare | $41.10 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $37.45 | 2024 | Opsumit |
| Abiomed | $33.85 | 2023-2024 | Impella |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27.08 | 2025 | |
| Grifols USA, LLC | $23.63 | 2023 | Gamunex-C |
| Ferring Pharmaceuticals INC. | $22.42 | 2023 | Rebyota |
| Glaxosmithkline, LLC. | $20.58 | 2025 | Nucala |
| Lexicon Pharmaceuticals, INC. | $19.87 | 2024 | Inpefa |
| Biomerieux INC | $19.82 | 2023 | Biofire Blood Culture Identification 2 (Bcid2) Panel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Atem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.